title: [Escherichia coli Nissle 1917 as safe vehicles for intestinal immune targeted therapy--a review].
abstract: It is difficult to stimulate efficient gut mucosal immune response to intestinal infection. This article critically reviews the research progressin Escherichia coli strain Nisslel917 ( EcN) actingas a safe vehicle for the intestinal mucosal immunity, to restore gastrointestinal disorder and relieve ulcerative colitis. EcN is an orally administered probiotics, combining the excellent colonization and non-immunogenic character, and can be an ideal live vector candidate. This strain could be a tumor-targeted delivery of TAT-Apoptin fusion gene to colorectal cancer. In the treatment of ulcerative colitis and Crohn's disease, the recombinant strain of EcN can be used as a target therapeutics for defensins presenting. Genetically modified EcN could be an ideal carrier organism for gut-focused in situ synthesis and expression of specific localized antigen delivery into the intestine, and stimulate specific mucosal immune response. In vitro trial demonstrated that intestinal recombinant E. coli Nissle-HA110-120 has the potential to stimulate antigen specific response, but EcN itself does not induce mucosal immune response and influence peripheral tolerance to self-antigen. At the same time, there are evidences that EcN is safe. Recombinant E. coli Nissle-HA110-120 does not migrate, clonally expand and activate specific CD4+ T cells, neither in healthy mice nor in other animals with acute colitis, even when the intestinal epithelium suffer from inflammation and the barrier function of the epithelial layer being destroyed.
authors.affiliation: College of Veterinary Medicine, Ministry of Education Key Lab for Avian Preventive Medicine, Yangzhou University, Yangzhou 225009, China. syxyBonnie@yeah.net
authors.forename: Pengpeng
authors.initials: P
authors.lastname: Xia
authors.forename: Jun
authors.initials: J
authors.lastname: Zhu
authors.forename: Guoqiang
authors.initials: G
authors.lastname: Zhu
mesh_terms: D000818:Animals; D004926:Escherichia coli / Q000235:genetics* / Q000378:metabolism; D015316:Genetic Therapy / Q000295:instrumentation / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007410:Intestinal Diseases / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D007413:Intestinal Mucosa / Q000276:immunology* / Q000382:microbiology; D051379:Mice